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Phosphocholine – an agonist of 
metabotropic but not of ionotropic 
functions of α9-containing nicotinic 
acetylcholine receptors
K. Richter1, V. Mathes1, M. Fronius2, M. Althaus3, A. Hecker1, G. Krasteva-Christ4, 
W. Padberg1, A. J. Hone5, J. M. McIntosh5,6,7, A. Zakrzewicz1 & V. Grau1
We demonstrated previously that phosphocholine and phosphocholine-modified macromolecules 
efficiently inhibit ATP-dependent release of interleukin-1β from human and murine monocytes 
by a mechanism involving nicotinic acetylcholine receptors (nAChR). Interleukin-1β is a potent 
pro-inflammatory cytokine of innate immunity that plays pivotal roles in host defence. Control of 
interleukin-1β release is vital as excessively high systemic levels cause life threatening inflammatory 
diseases. In spite of its structural similarity to acetylcholine, there are no other reports on interactions 
of phosphocholine with nAChR. In this study, we demonstrate that phosphocholine inhibits ion-channel 
function of ATP receptor P2X7 in monocytic cells via nAChR containing α9 and α10 subunits. In stark 
contrast to choline, phosphocholine does not evoke ion current responses in Xenopus laevis oocytes, 
which heterologously express functional homomeric nAChR composed of α9 subunits or heteromeric 
receptors containing α9 and α10 subunits. Preincubation of these oocytes with phosphocholine, 
however, attenuated choline-induced ion current changes, suggesting that phosphocholine may act as 
a silent agonist. We conclude that phophocholine activates immuno-modulatory nAChR expressed by 
monocytes but does not stimulate canonical ionotropic receptor functions.
Phosphocholine (PC) is a precursor as well as a degradation product of phosphatidylcholine (lecithin), a major 
phospholipid of eukaryotic bio-membranes1,2. Beside the important role of PC for eukaryotic bio-membranes, 
PC moieties can be covalently attached to proteins and glycolipids of plants3, fungi4, eukaryotic parasites5, and 
some pathogenic bacteria6,7. PC and PC-modified macromolecules interact with C-reactive protein (CRP), a 
classical acute phase reactant8,9, or with natural antibodies7,10. These interactions may induce complement fix-
ation and other effector mechanisms involved in host defence. In contrast, PC-modified macromolecules are 
also known to provoke strong anti-inflammatory effects and contribute to immune evasion of parasites5,11. For 
example, PC-modified lipopolysaccharide (LPS) from Haemophilus influenzae contributes to bacterial virulence 
and enables persistent host colonization6,12,13. The mechanisms, regarding how PC-modified macromolecules 
initiate immune evasion, are not fully understood. PC-modifications on the surface of H. influenzae might be a 
kind of molecular mimicry preventing activation of Toll-like receptors (TLR)14,15. Interestingly, Myd88, an adap-
tor molecule involved in signalling of TLR and interleukin-1 (IL-1) seems to be of importance, as wild-type and 
PC-deficient H. influenzae strains are cleared at the same pace in Myd88-deficient mice15.
Two isoforms of the pro-inflammatory cytokine IL-1 exist, IL-1α and IL-1β , which signal via the same recep-
tors and play a central role in host defence against infections16. IL-1α mainly acts locally within infected tissues, 
whereas IL-1β exerts more systemic effects16. High concentrations of circulating IL-1β , however, can cause 
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life-threatening systemic inflammatory response syndrome (SIRS)17. Hence, IL-1β release is tightly controlled and 
the underlying mechanisms are of significant clinical interest. Production of mature IL-1β by human monocytes 
and macrophages typically depends on two consecutive danger signals such as LPS and extracellular ATP18,19. 
LPS activates TLR-4 and induces the biosynthesis of pro-IL-1β that remains within the cytoplasm, unless the cell 
becomes activated by another danger signal. Extracellular ATP originating from damaged neighbouring cells typ-
ically binds to ATP-receptor P2X7, induces efflux of K+ ions, assembly of the NLRP3 inflammasome, activation of 
the proteolytic activity of caspase-1, cleavage of pro-IL-1β , and release of mature bioactive IL-1β 18,19.
Recently, we demonstrated that free PC and PC-modified macromolecules dose-dependently inhibit 
ATP-induced release of IL-1β by human monocytic cells20. In the same study we showed that a similar effect 
is provoked by nicotine, acetylcholine (ACh) and choline (Cho)20. The inhibitory effect of PC moieties is 
Figure 1. Choline and phosphocholine inhibit BzATP-induced IL-1β release from U937 cells via nicotinic 
acetylcholine receptor containing α9 and α10 subunits. (a) Human monocytic U937 cells were primed with 
lipopolysaccharide (LPS, 1 µg/ml, 5 h) followed by stimulation with BzATP (100 µM, 30 min) in the presence 
or absence of phosphocholine (PC, 100 µM), choline (Cho, 100 µM) and/or different concentrations of the 
α-conotoxin RgIA4, a specific antagonist of α9α10 nicotinic acetylcholine receptors (nAChR). Interleukin-1β 
(IL-1β) released into the culture medium was measured by enzyme linked immunosorbent assay (ELISA). In 
control experiments, cells were left untreated (C1), primed with LPS (C2) or with LPS followed by BzATP (C3). 
In the presence of PC as well as Cho the IL-1β release was inhibited. The inhibitory effect of PC and Cho was 
dose-dependently antagonized by RgIA4 (*P ≤ 0.05, **P ≤ 0.01, significantly different from cells treated with PC 
or Cho alone, Mann-Whitney rank-sum test). (b) In LPS-primed U937 cells that were transfected with control 
siRNA (si) the BzATP-stimulated IL-1β release was inhibited by PC and Cho. In cells transfected with siRNA 
to Chrna9 or Chrna10, the effects of PC and Cho were blunted (*P ≤ 0.05, different from cells treated with LPS 
and BzATP; #P ≤ 0.05, ##P ≤ 0.01, different from respective experiments on cells treated with control siRNA; 
Kruskal-Wallis followed by Mann-Whitney rank-sum test). Data are presented as individual data points, bar 
represents median, whiskers percentiles 25 and 75.
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antagonized by mecamylamine (Mec), α -bungarotoxin and strychnine, suggesting that nicotinic acetylcholine 
receptors (nAChR) containing α 9 and/or α 10 subunits are involved in signalling20. Interestingly, nicotine abol-
ishes ATP-induced ion channel functions of P2X7 receptors in U937 cells, a human monocytic cell line, but does 
not provoke ion currents itself 20.
The purpose of this study was to test the hypothesis that binding of PC and Cho to nAChR inhibit P2X7 recep-
tor function similar to nicotine. In addition, we hypothesised that PC is a novel agonist of nAChR containing α 9 
and/or α 10 subunits and directly compare the effects of PC to the well-known α 9* (* indicates the possible pres-
ence of additional nAChR subunits) agonist Cho21. We provide evidence that PC and Cho induce metabotropic 
effects via α 9α 10* -containing nAChR in monocytic cells that result in an inhibition of P2X7 receptor function. 
Canonical ionotropic functions of α 9* nAChR, however, are triggered by Cho but strikingly not by PC.
Results
PC and Cho inhibit BzATP-induced IL-1β release via α9 and α10 nAChR subunits. To test the 
hypothesis, that the inhibitory effects of PC and Cho are mediated via nAChR containing α 9 and/or α 10 subunits, 
we used an analogue of α -conotoxin RgIA (RgIA4, synonym CSP-4), a potent and selective antagonist of human 
α 9* nAChR22,23. Human monocytic U937 cells were primed with LPS for 5 h followed by stimulation with the 
selective P2X7 agonist BzATP (2′ (3′ )-O-(4-benzoyl-benzoyl)ATP trieethylammonium salt)24 for another 30 min 
in the presence or absence of PC, Cho and/or RgIA4. Thereafter, IL-1β released into the culture medium was 
measured by an enzyme linked immunosorbent assay (ELISA; Fig. 1). As expected, PC or Cho (100 μ M each) 
completely inhibited BzATP-induced IL-1β release (Fig. 1a). RgIA4 fully antagonized the inhibitory effect of PC 
and Cho in a dose-dependent manner (IC50 about 10 nM; n = 6; P ≤ 0.05; Fig. 1a).
To corroborate these results, we transfected U937 cells with small interfering RNA (siRNA) to silence the 
expression of α 9 and α 10 nAChR subunits or with scrambled control siRNA. The efficiency of this treatment in 
U937 cells was shown before20. Transfection of control siRNA neither impaired BzATP-induced release of IL-1β 
nor altered the inhibitory effects of PC and Cho (n = 4; P ≤ 0.05; Fig. 1b). In contrast, when the expression of α 9 
or α 10 subunits was silenced by siRNA the inhibitory effect of PC as well as Cho was blunted (n = 4; P ≤ 0.05; 
Fig. 1b).
Furthermore, we investigated BzATP-induced IL-1β release by peripheral blood mononuclear leukocytes 
(PBMC) isolated from Chrna9 and from Chrna10 gene-deficient mice (Chrna9 − /− ; Chrna10 − /− ) as well as 
from two corresponding wild-type (WT) strains (Chrna9 + /+ ; Chrna10 + /+ ). BzATP consistently induced 
release of IL-1β from WT and gene-deficient PBMC (n ≥ 4; Fig. 2). PC or Cho (100 μ M each) significantly 
reduced BzATP-induced IL-1β release from PBMC isolated from Chrna9 + /+ (n = 6; P ≤ 0.01) and Chrna10 + /+ 
(n = 4; P ≤ 0.05) mouse strains (Fig. 2). In contrast, PC and Cho were ineffective in PBMC from Chrna9 − /− or 
Chrna10 − /− mice (n ≥ 5; P ≥ 0.05; Fig. 2).
Figure 2. Choline and phosphocholine do not inhibit BzATP-induced IL-1β release from mononuclear 
leukocytes of Chrna9 and Chrna10 gene-deficient mice. (a,b) Mononuclear leukocytes were isolated from 
Chrna9 and Chrna10 gene-deficient mice (white circle; Chrna9 −/−; Chrna10 −/−) and corresponding 
wild-type mice (black circle; Chrna9 +/+; Chrna10 +/+). BzATP (100 µM) induced release of interleukin-1β 
(IL-1β) was investigated in the presence of phosphocholine (PC; 100 µM) or choline (Cho; 100 µM). PC and 
Cho suppressed BzATP-induced release of IL-1β in all WT strains investigated. In sharp contrast, no inhibition 
of IL-1β release was seen in Chrna9 −/− and Chrna10 −/− mice deficient in α9 or α10 subunit containing 
nicotinic acetylcholine receptors, suggesting that both subunits are needed (*P ≤ 0.05, **P ≤ 0.01, significantly 
different from cells treated with PC or Cho alone, Mann-Whitney rank-sum test). Data are presented as 
individual data points, bar represents median, whiskers percentiles 25 and 75.
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At the end of each experiment, lactate dehydrogenase (LDH) levels were determined to test for cell viability. As 
shown in Table 1 and Table 2, LDH values remained below 10% of the total release, irrespective of the experiment 
performed.
PC and Cho inhibit BzATP-induced ion current stimulation in U937 cells. To investigate if 
BzATP-induced ion current stimulation due to P2X7 receptor activation is inhibited by PC and Cho, we per-
formed whole-cell patch-clamp measurements on LPS-primed U937 cells. As shown previously20, application 
of BzATP (100 μ M) consistently induced ion currents (Fig. 3a,d). BzATP-induced ion current stimulation was 
reversible by washout and repeatable (Fig. 3a,d). No significant changes were detected when comparing the ampli-
tude (∆ IBzATP) of the first BzATP-induced response with the second (n = 10, P = 0.241; Fig. 3d), indicating that 
the receptors do not desensitise under these conditions. In the next set of experiments BzATP was first applied 
alone, which provoked ion currents (Fig. 3b). After washout, the cells were preincubated with Cho (100 μ M) 
for 30 s, followed by an additional application of BzATP (Fig. 3b). Cho alone did not cause any changes in current 
(n = 7, Fig. 3b). Moreover, Cho abolished BzATP-induced current stimulation (n = 7, P = 0.018; Fig. 3b,d). In the 
next experiments, cells were preincubated with the nAChR antagonist Mec (100 μ M), followed by application of 
Cho (Fig. 3c). Under these conditions (Mec + Cho) a BzATP-induced current stimulation was detectable and the 
first and second BzATP-induced effects did not differ (n = 5, P = 0.5; Fig. 3c,d).
We performed the same kind of experiments using PC (1 mM) instead of Cho (Fig. 4). PC alone did not induce 
ion current changes. The BzATP-induced effect was abolished in presence of PC (n = 6, P = 0.028; Fig. 4a,d). 
Furthermore, the inhibitory effect of PC was antagonized by preincubation of the cells with Mec and the first and 
second BzATP-induced effect did not differ (n = 6, P = 0.209; Fig. 4b,d). Taken together, we were able to show that 
PC and Cho inhibit BzATP-induced ion fluxes in U937 cells.
Previous experiments examining the inhibition of BzATP-induced IL-1β release by PC provided evidence that 
nAChR containing subunits α 9 and/or α 10 are involved (Fig. 1). To confirm these data, we performed whole-cell 
patch-clamp measurements in the presence of RgIA4 (200 nM) (Fig. 4c). For this purpose, the BzATP-induced 
current was determined (n = 6; Fig. 4c). After washout of BzATP, cells were preincubated with RgIA4 and fol-
lowed by PC application (Fig. 4c). Subsequent application of BzATP activated a current that was similar to the 
Cell treatment Cell death [%] Mean ± SEM n
– 2.14 ± 0.87 6
LPS 2.23 ± 0.91 6
LPS, BzATP 1.65 ± 0.67 6
LPS, BzATP, PC 1.76 ± 0.72 6
LPS, BzATP, PC, RgIA4 200 nM 2.38 ± 0.97 6
LPS, BzATP, PC, RgIA4 20 nM 1.48 ± 0.60 6
LPS, BzATP, PC, RgIA4 2 nM 2.30 ± 0.94 6
LPS, BzATP, PC, RgIA4 0.2 nM 1.76 ± 0.72 6
LPS, BzATP, Cho 1.30 ± 0.53 6
LPS, BzATP, Cho, RgIA4 200 nM 1.50 ± 0.61 6
LPS, BzATP, Cho, RgIA4 20 nM 1.54 ± 0.63 6
LPS, BzATP, Cho, RgIA4 2 nM 1.66 ± 0.68 6
LPS, BzATP, Cho, RgIA4 0.2 M 2.09 ± 0.85 6
si control: LPS 4.96 ± 2.48 4
si control: LPS, BzATP 5.04 ± 2.52 4
si control: LPS, BzATP, PC 5.41 ± 2.71 4
si control: LPS, BzATP, Cho 5.13 ± 2.57 4
si Chrna9: LPS 4.55 ± 2.27 4
si Chrna9: LPS, BzATP 5.20 ± 2.60 4
si Chrna9: LPS, BzATP, PC 5.13 ± 2.56 4
si Chrna9: LPS, BzATP, Cho 5.00 ± 2.50 4
si Chrna10: LPS 2.48 ± 1.01 6
si Chrna10: LPS, BzATP 3.25 ± 1.33 6
si Chrna10: LPS, BzATP, PC 3.00 ± 1.22 6
si Chrna10: LPS, BzATP, Cho 2.96 ± 1.21 6
Table 1. Lactate dehydrogenase (LDH) release of U937 cells. Human monocytic U937 cells were primed for 
5 h with lipopolysaccharide (LPS, from Escherichia coli; 1 μ g/ml). Subsequent, BzATP (100 μ M) was applied  
for another 30 min in presence or absence of the nAChR agonist phosphocholine (PC; 100 μ M) or choline 
(Cho; 100 μ M) or α -conotoxin RgIA4. In some experiments the expression of nAChR containing the α 9 or  
α 10 subunit was reduced by using the small interfering RNA (si) transfection. At the end of the experiments, 
LDH was measured in the cell culture supernatants and is given as % of total release (mean ± standard error of 
mean, SEM).
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preceding BzATP current (n = 6, P = 0.173; Fig. 4c,d), suggesting that RgIA4 fully antagonized the inhibitory 
Genotype Cell treatment Cell death [%] Mean ± SEM n
Chrna9 + /+ – 6.90 ± 1.50 6
Chrna9 + /+ BzATP 6.97 ± 1.37 6
Chrna9 + /+ BzATP, PC 6.62 ± 1.06 6
Chrna9 + /+ BzATP, Cho 6.71 ± 1.23 6
Chrna9 − /− – 8.64 ± 0.93 5
Chrna9 − /− BzATP 7.63 ± 1.09 5
Chrna9 − /− BzATP, PC 7.96 ± 0.91 5
Chrna9 − /− BzATP, Cho 8.62 ± 1.06 5
Chrna10 + /+ – 4.38 ± 0.95 4
Chrna10 + /+ BzATP 5.04 ± 2.04 4
Chrna10 + /+ BzATP, PC 4.81 ± 1.96 4
Chrna10 + /+ BzATP, Cho 5.96 ± 1.89 4
Chrna10 − /− – 6.35 ± 1.18 6
Chrna10 − /− BzATP 6.42 ± 1.13 6
Chrna10 − /− BzATP, PC 6.40 ± 1.30 6
Chrna10 − /− BzATP, Cho 7.68 ± 1.38 5
Table 2. Lactate dehydrogenase (LDH) measurement of peripheral blood mononuclear leukocytes (PBMC). 
Peripheral blood mononuclear leukocytes (PBMC) were isolated from Chrna9 gene-deficient (Chrna9 − /− ) and 
Chrna10 (Chrna10 − /− ) gene-deficient mice as well as from two corresponding wild-type (WT) strains. LDH 
was measured in the cell culture supernatants at the end of the experiments, and is given as % of total release 
(mean ± standard error of mean, SEM). Untreated cells are marked by “–”. BzATP (100 μ M) was applied in the 
presence and absence of phosphocholine (PC; 100 μ M) or choline (Cho; 100 μ M).
Figure 3. Choline inhibits BzATP-induced ion current stimulation in U937 cells. Whole-cell patch-clamp 
measurements were performed on human monocytic U937 cells primed with lipopolysaccharide (1 µg/ml, 5 h).  
Depicted are representative current curves (a,c). (a,d) In control experiments, consecutive application of the 
P2X7 receptor agonist BzATP (100 µM, grey bar) induced repetitive ion current stimulations (BzATP1 and 2). 
(b,d). After washout of the first BzATP stimulus, choline (Cho, 100 µM, dark grey bars) was applied. In presence 
of Cho, BzATP did not change the ion current. (c,d) Mecamylamine (Mec, 100 µM, white bar) antagonized 
the inhibitory effect of Cho. All BzATP-induced current changes (∆IBzATP) are shown as individual data points, 
bars represent median, whiskers percentiles 25 and 75. Statistical analyses were performed using the Wilcoxon 
signed-rank test.
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effect of PC.
PC does not induce ion current stimulation in Xenopus laevis oocytes expressing α9 or α9α10 
nAChR. Cho is an agonist of nAChR containing α 9 subunits21. To test if PC also evokes ion currents at canon-
ical α 9 containing receptors, human α 9 subunit as well as a combination of human α 9 and α 10 subunits were 
heterologously expressed in Xenopus laevis oocytes. Two-electrode voltage-clamp (TEVC) measurements were 
performed to assess ion channel functions of nAChR.
In oocytes expressing homomeric α 9 nAChR, application of Cho (Cho1) resulted in a rapid stimulation of 
the transmembrane current (IM; Fig. 5a,c). The effect of Cho was reversible upon washout (Fig. 5a). Subsequent 
application of Cho (Cho2) activated a current that was significantly smaller than the preceding Cho-induced 
current (n = 14, P = 0.005; Fig. 5a,c). In contrast, when PC was applied for 2 min, no ion currents were provoked 
(Fig. 5b). As an internal positive control, Cho was applied at the end of each experiment resulting in a significant 
current stimulation (n = 12, P = 0.002; Fig. 5c).
The same kinds of experiments were performed on oocytes co-expressing nAChR subunits α 9 and α 10. 
Application of Cho induced a current stimulation (Fig. 5d,f). In comparison to the Cho-induced effect in oocytes 
expressing α 9 (Fig. 5a), the current stimulation was faster and shorter (Fig. 5d). The Cho effect was repeatable and 
significantly blunted compared to the first response (n = 12, P = 0.003; Fig. 5f). Again, application of PC had no 
impact on the current while Cho induced a current stimulation (n = 10, P = 0.005; Fig. 5e,f). Neither application 
of Cho (n = 17) nor PC (n = 11) induced changes in currents of water injected control oocytes, which did neither 
express human α 9 nor α 10 nAChR subunits (Fig. 5g,h).
PC interacts with heterologously expressed α9α10 nAChR. Since PC did not evoke ion currents 
in oocytes expressing homomeric α 9 and heteromeric α 9α 10 nAChR, we questioned whether PC might func-
tion as a silent desensitiser or as an antagonist of α 9* nAChR containing subtypes. Therefore, we performed 
an additional set of experiments designed to monitor the effects of PC on the Cho-evoked responses over time 
(Fig. 6a,b). Oocytes expressing heteromeric α 9α 10 nAChR were stimulated with Cho once per min until a 
Figure 4. The inhibitory effect of phosphocholine on BzATP-mediated ion current stimulation is 
antagonized by α-conotoxin RgIA4. Whole-cell patch-clamp measurements were performed on human 
monocytic U937 cells primed with lipopolysaccharide (1 µg/ml, 5 h). (a) Application of the P2X7 receptor 
agonist BzATP (100 µM, grey bar) induced an ion current stimulation (BzATP1). After washout of BzATP1, 
phosphocholine (PC, 1 mM, dark grey bars) was applied. In presence of PC, BzATP did not change the ion 
current (BzATP2). (b,c,d) Mecamylamine (Mec, 100 µM, white bar, (b) as well as RgIA4 (200 nM, white bar; 
(c) antagonized the inhibitory effect of PC. (d) In parallel performed control experiments application of BzATP 
induced repetitive ion current stimulations that did not differ (current curve not shown). All ∆IBzATP values are 
shown as individual data points, bars represent median, whiskers percentiles 25 and 75. Statistical analyses were 
performed using the Wilcoxon signed-rank test.
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Figure 5. Phosphocholine does not induce ion channel functions in Xenopus laevis oocytes that 
heterologously express α9 or α9α10 nicotinic acetylcholine receptors. Two-electrode voltage-clamp 
(TEVC) measurements were performed on oocytes that heterologously expressed human α9 alone (a–c) or a 
combination of α9 and α10 (d–f) nicotinic acetylcholine receptor (nAChR) subunits. (a,d) Choline (Cho, 1 
mM, black bars) induced repetitive stimulations of the transmembrane ion current (IM) in oocytes transfected 
with α9 (a) and in oocytes co-expressing α9α10 nAChR subunits (d). The second Cho-induced effect (Cho2) 
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steady-state baseline was achieved. Then, the perfusion solution was switched to one containing 1 mM PC and 
the Cho-evoked responses were monitored for changes in amplitude. Under these conditions, PC decreased the 
Cho-evoked responses to 13.1 ± 3.3% (n = 5) of control values after a 20 min perfusion (Fig. 6b). PC was then 
washed out and Cho-evoked responses were monitored for recovery from inhibition. The responses recovered to 
98.2 ± 8.2% (n = 5) of control values after a 15 min perfusion with control solution.
Discussion
In the present study, we identify PC as a novel agonist of monocytic nAChR containing subunits α 9 and α 10. We 
provide evidence that α 9 and α 10 nAChR subunits are essential for the PC-mediated inhibition of ATP-induced 
ion channel functions at P2X7 receptor in monocytic cells and hence, for the inhibition of ATP-induced release 
of IL-1β . Cho, a well-known agonist of nAChR containing α 9 subunits21, and PC provoke similar metabotropic 
but no ionotropic effects in monocytic cells. As expected, Cho induces ion current responses at conventional 
ionotropic α 9 nAChR homomers or α 9α 10 heteromers. In stark contrast, PC does not provoke any ion current 
changes at these canonical ionotropic receptors. To the best of our knowledge, we are the first to describe an ago-
nist of nAChR containing α 9 subunits that triggers metabotropic but no ionotropic receptor functions.
In the first part of this study, we demonstrated that PC and Cho are agonists of metabotropic nAChR com-
posed of α 9 and α 10 subunits in monocytic cells. We showed previously that PC and Cho dose-dependently 
inhibit the ATP-induced release of IL-1β from LPS-primed human monocytic U937 cells via nAChR that are sen-
sitive to Mec, α -bungarotoxin and strychnine20. Here, we clarified that PC and Cho act as ligands of monocytic α 
9* nAChR by using the potent and selective antagonist RgIA4 which dose-dependently antagonized the inhibi-
tion of IL-1β release. These findings were further confirmed by gene-silencing experiments in U937 cells: silenc-
ing of Chrna9 expression blunted the inhibitory effects of PC and Cho. The same observation was made, when 
Chrna10 gene expression was silenced, suggesting that α 9 and α 10 nAChR subunits cooperate in monocytic cells.
The results of the gene-silencing experiments suggested but did not prove that α 9 and α 10 nAChR subunits 
are essential for the signalling of PC and Cho in monocytes. Therefore to corroborate the role of α 9 nAChR 
subunit by an independent approach, we investigated freshly isolated PBMC from wild-type and gene-deficient 
mice. Although primary mouse PBMC were not intentionally primed to induce biosynthesis of IL-1β , they con-
sistently released IL-1β in response to stimulation with BzATP. These observations are in accordance with pre-
vious findings on primary human PBMC20,25. We assume that freshly isolated PBMC became activated during 
cell isolation and culture20. As expected, PC and Cho efficiently inhibited the BzATP-induced release of IL-1β 
by PBMC obtained from wild-type mice but did not impair the IL-1β release from PBMC of Chrna9 − /− and 
Chrna10 − /− mice. From these data, we conclude that α 9 and α 10 subunits are essential for signalling of PC and 
Cho. Interactions of the α 9 and α 10 nAChR subunits were previously described. Subunits α 10 do not assemble 
into functional ionotropic homomeric nAChR26, while co-expression of α 9 and α 10 nAChR subunits results in 
formation of functional heteromeric α 9α 10 nAChR26–28. Transcripts of α 9 and α 10 nAChR subunits have been 
detected in the auditory system26,29, dorsal root ganglion30, skin31, as well as in mononuclear leukocytes20,32,33 
including human monocytic cells20.
Next, we confirmed our hypothesis that PC and Cho inhibit ATP-mediated ion current responses in mono-
cytic cells. In accordance with our previous study20, we detected BzATP-induced ion current responses in 
whole-cell patch-clamp measurements on LPS-primed U937 cells. These currents are most likely due to activation 
of P2X7 receptors, as BzATP is a specific agonist of this ATP-receptor34, and due to a consecutive opening of pan-
nexin hemichannels35,36. In line with our hypothesis, BzATP-mediated P2X7 receptor activation was completely 
abolished in presence of PC and Cho. This inhibitory effect was antagonized by the general nicotinic antagonist 
Mec and the α 9* -specific conotoxin RgIA4. These results corroborate the involvement of α 9 and/or α 10 nAChR 
subunits in signalling of PC. A functional interaction of other subtypes of nAChR and P2X receptors was demon-
strated previously in neurons37 and in heterologous expression systems38,39. In these studies, co-application of 
ATP and nicotinic agonists evoked current responses that were smaller than the sum of the individual currents 
induced by ATP and ACh or nicotine37,38. In the present study, PC or Cho alone did not evoke any ion current 
responses in U937 cells, consistent with functional coupling of a non-canonical metabotropic nAChR to iono-
tropic P2X7 receptors. While in excitable cells such as neurons nAChR are ligand-gated ion channels, no iono-
tropic nAChR functions have been observed in leukocytes20,32,33,40. At present, we do not know how activation of 
monocytic nAChR by PC or Cho translates into the observed inhibition of P2X7 receptor function.
In the last part of the study, we investigated the effect of PC at canonical ionotropic nAChR using Xenopus 
laevis oocytes as a heterologous expression system for human homomeric α 9 nAChR as well as heteromeric α 9α 10 
nAChR. Cho was included in these experiments as a positive control and transmembrane ion currents were 
recorded in TEVC measurements. We detected Cho-induced current responses in oocytes expressing homomeric 
α 9 and heteromeric α 9α 10 nAChR. Current responses to the first Cho application for 30 s varied from 50 nA to 
1200 nA (see Fig. 5a,f). Subsequent application of Cho resulted in smaller current responses, indicating receptor 
was smaller compared to the first one (Cho1) indicating receptor desensitization. (b,e) Initial application of 
phosphocholine (PC, 1 mM, white bars) had no impact on IM, whereas application of Cho thereafter induced a 
current stimulation. Again, oocytes expressing only α9 and those co-expressing α9α10 nAChR subunits led to 
similar results. (g,h) Representative current traces of water injected control oocytes (no expression of human 
receptors). Neither repeated application of Cho (n = 17), nor PC (n = 11) induced any changes in IM. Depicted 
are representative current curves (a,b,d,e,g,h). All changes of the transmembrane current (∆IM) induced by 
cholinergic stimulation are shown as individual data points, bars represent median, whiskers percentiles 25 and 
75 (c,f). Statistical analyses were performed using the Wilcoxon signed-rank test.
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desensitisation. This is in contrast to previous studies and to our own observations, where application of ACh 
or Cho in short 1 s pulses resulted in repeatable current responses without desensitisation27,41. We assume that 
receptor desensitisation is a consequence of extended exposure of nAChR to Cho.
In sharp contrast to Cho, PC did not evoke ion current responses in α 9 and/or α 9α 10 nAChR expressing 
oocytes. We conclude that at least in our experimental settings, PC is an agonist of metabotropic nAChR con-
taining α 9* subunits, whereas it does not stimulate canonical ligand-gated nAChR functions. This finding sug-
gests that PC acts as a potent regulator of innate immunity but does not activate current responses in neuronal 
or non-neuronal cells expressing canonical ionotropic nAChR containing α 9 subunits. Hence, PC and other 
molecules containing a PC group may be promising therapeutics for the prevention and treatment of excessive 
inflammation involving IL-1β such as life-threatening SIRS, without entailing the risk of adverse effects involving 
excitable cells.
Although PC did not trigger ion channel functions at α 9 and α 9α 10 subunit containing nAChR expressed by 
Xenopus laevis oocytes, we obtained evidence that PC interacts with these canonical receptors and hypothesised 
that PC might act as a silent agonist. Per definition, silent agonists desensitise receptors without activating their 
function42,43. To further asses this, we used α 9α 10 nAChR expressing oocytes in an experimental setup that ena-
bled application of Cho in 1 s pulses every 60 s, where Cho induced repetitive current responses without receptor 
desensitisation. We found that responses to Cho at heteromeric α 9α 10 nAChR were blunted in the presence of 
PC. The observed slow kinetics of inhibition and recovery from inhibition by PC was consistent with silent desen-
sitisation. However, we should point out that our results do not rule out that the observed inhibition by PC is due 
to simple antagonism. Nicotine is an example of a ligand, which acts as an antagonist at ionotropic receptors44 
containing α 9 subunits, but acts as an agonist at monocytic metabotropic α 9 nAChR that inhibit P2X7 function20. 
A silent agonist for homomeric nAChR was recently reported for homomeric α 7 nAChR43. These authors showed 
that ACh-induced current responses were reduced after preincubation of the oocytes with compound NS674043.
In conclusion, we identified PC as a novel agonist of metabotropic nAChR containing α 9 and α 10 subunits. 
PC and Cho evoke no ion current responses at these receptors expressed by monocytes but efficiently inhibit 
ATP-mediated P2X7 receptor activation and release of IL-1β . In contrast to Cho, PC does not trigger ionotropic 
functions at canonical human α 9 nAChR homomers and α 9α 10 nAChR heteromers. These findings suggest that 
PC may be a valuable active substance for the treatment of inflammatory diseases that targets nAChR of mono-
cytes without disturbing ionotropic functions of excitable cells.
Methods
U937 cell culture and stimulation. U937 cells were obtained from the German Collection of 
Microorganisms and Cell Cultures (Braunschweig, Germany). The cells were cultured in RPMI 1640 (Gibco 
by Life Technologies GmbH, Darmstadt, Germany) supplemented with 10% fetal calf serum (FCS; Biochrome, 
Berlin, Germany) and 2 mM L-glutamine (Gibco by Life Technologies GmbH) under 5% CO2 atmosphere at 37 °C.
Figure 6. Phosphocholine inhibits choline-gated currents mediated by α9α10 nicotinic acetylcholine 
receptors heterologously expressed by Xenopus laevis oocytes. Two-electrode voltage-clamp experiments 
were performed on oocytes that heterologously expressed human α9α10 nicotinic acetylcholine receptors as 
described in Methods. (a) Representative current traces showing the inhibitory effects of phosphocholine  
(PC, 1 mM) on choline-gated currents (Cho, 1 mM). The current traces are each from 30 s recordings and 
are shown concatenated (omitting the 30 s gap between each individually recorded trace). Oocytes were 
continuously perfused with control solution and stimulated with 1 sec pulses of Cho once per min until steady-
state baseline responses were observed (indicated by the arrow). Subsequently, the control solution was changed 
to one containing PC and the Cho-gated currents monitored for changes in amplitude for 20 min. Thereafter, 
PC was washed out and recovery from inhibition by PC monitored. (b) Analysis of inhibition and recovery from 
inhibition of Cho-gated currents by PC. The error bars denote the standard error of mean (SEM) from 5 oocytes.
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To investigate IL-1β release cells were transferred to 24-well plates (1 × 106 cells/ml and per well). Cells were 
primed with 1 μ g/ml LPS from Escherichia coli (L2654; 1 μ g/ml; Sigma-Aldrich, Deisenhofen, Germany) for 5 h. 
After priming, the P2X7 receptor agonist BzATP (Sigma-Aldrich; 100 μ M) was added for 30 min in presence or 
absence of different concentrations of cholinergic agonists and antagonists. Cho chloride (100 μ M), PC chloride 
calcium salt tetrahydrate (100 μ M), and Mec hydrochloride (100 μ M) were purchased from Sigma-Aldrich. An 
analogue of α -conotoxin RgIA (RgIA4)22 was used in concentrations from 0.2 to 200 nM. After cell treatment, 
cells were spun down (500 g, 8 min) the supernatants were collected and stored at − 20 °C. IL-1β concentrations 
were measured using a human Quantikine Immunoassays (R&D Systems, Minneapolis, MN) and LDH was 
determined.
Silencing of α9 and α10 nAChR subunit expression. In some experiments the expression of nAChR 
containing the α 9 and/or α 10 subunits in U937 cells was reduced by using siRNA technology. U937 cells were 
transfected with ON-TARGETplus human Chrna9 or Chrna10 siRNA SMARTpool (Thermo Fisher Scientific, 
Schwerte, Germany). As a control for unspecific effects of siRNA transfection cells were transfected with negative 
control ON-TARGETplus Non-targeting Control Pool (Thermo Fisher Scientific). In accordance with the manu-
facturer’s protocol, all cells were transfected with 30 pM siRNA/1 × 106 cells using Amaxa Cell Line Nucleofector 
Kit C and Nucleofector II Device (both from Lonza Cologne, Cologne, Germany). 48 h after siRNA transfection, 
IL-1β release experiments were performed.
Mononuclear leukocytes from Chrna9 and Chrna10 gene-deficient mice. Male and female 
gene-deficient Chrna9 (129S-Chrna9tm1Bedv/J)45 and Chrna10 (129S4-Chrna10tm1Bedv/Mmucd)46 as well as corre-
sponding WT mice (for details see45,46) were used for isolation of PBMC. Experimental animals received humane 
care according to NIH “Guide for the Care and Use of Laboratory Animals”. Animal experiments were approved 
by the local committee at the Regierungspräsidium Giessen, Hesse, Germany (permit No. Gi 20/23-A10/2011).
Mice were euthanized by neck dislocation, and blood was drawn from the caval vein into heparinized syringes. 
PBMC were separated by discontinuous Percoll (Ge Healthcare Bio-Sciences AB, Uppsala, Sweden; 1.082 g/ml) 
density gradient centrifugation and cultured for 2 h in RPMI 1640 (Gibco by Life Technologies GmbH) supple-
mented with 10% FCS (Biochrome) and 2 mM L-glutamine (Gibco by Life Technologies GmbH), at 5% CO2 and 
37 °C. For investigation of IL-1β release, BzATP (Sigma-Aldrich; 100 μ M) was added for 30 min in the presence 
or absence of PC (100 μ M) or Cho (100 μ M). Subsequently, cell culture supernatants were collected and stored 
at − 20 °C. Finally, IL-1β concentrations were measured by using mouse Quantikine IL-1β Immunoassay (R&D 
Systems).
LDH measurements. In order to test for cell viability, activity of the cytoplasmic enzyme LDH was assayed 
by the Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI) according to the supplier’s instructions. 
LDH in the cell culture supernatants of U937 cells and PBMC was measured at the end of the experiments. For 
calculating the proportion of dead cells, a maximum LDH release control was generated. For this purpose, U937 
cells were lysed by freezing them twice (− 80 °C). Subsequently, the samples were analysed according to the sup-
plier’s instructions and values determined in cell culture supernatants were compared with the total content of 
LDH in lysed cells.
Whole-cell patch-clamp recordings on U937 cells. For electrophysiological recordings, U937 cells 
were placed in poly-L-lysine coated cell culture dishes (Nunc, Roskilde, Denmark) containing bath solution 
(in mM: 5.4 KCl, 120 NaCl, 2 CaCl2, 1 MgCl2, 25 glucose and 10 HEPES (4-(2-hydroxyethyl)-piperazine-1-eth
anesulfonic acid); pH 7.4).
Patch pipettes with a resistance of 2–3 MΩ were pulled from borosilicate glass capillaries (Hilgenberg, 
Malsfeld, Germany) using a dmz-puller (Zeitz, Augsburg, Germany) and filled with a pipette solution (in mM: 
120 KCl, 1 CaCl2, 2 MgCl2, 10 HEPES, 11 EGTA (ethylene glycol tetraacetic acid), and 20 glucose; pH 7.3). After 
5 h incubation with LPS, whole-cell patch-clamp recordings were performed at room temperature. Cells were 
clamped to − 60 mV and transmembrane currents were recorded using an EPC-9 amplifier (HEKA, Lambrecht, 
Germany) and acquired via an ITC-16 interface with Pulse software (HEKA). BzATP (100 μ M), PC (1 mM), Cho 
(100 μ M), RgIA4 (200 nM) and Mec (100 μ M) were dissolved in bath solution and applied via a pressure-driven 
microperfusion system. Rg1A4 (sequence ID3) was prepared as previously described22. All chemicals used for 
preparation of bath and pipette solution were purchased from Fluka (Deisenhofen, Germany), except for HEPES 
and EGTA (Sigma-Aldrich).
At least once per measuring day respective control experiments were performed in which BzATP was applied 
twice and the BzATP-induced effect was tested for reversibility and repeatability.
Heterologous expression of human nAChR in oocytes and TEVC measurements. Oocytes were 
obtained from adult female South African Clawed Frogs (Xenopus laevis; Xenopus-Express, Le Bourg, France). 
Manipulations of animals were conducted in accordance to the guidelines of the German law of animal care and 
were authorized by the local committee at the Regierungspräsidium Giessen, Hesse, Germany (permit num-
ber 400_M and 478_M). Oocytes were separated by collagenase treatment (1.5 mg/ml; Biochem, Karlsruhe, 
Germany) for 90 min. The follicle layer was removed by incubation of cells in Ca2+-free oocyte Ringer’s solution 
(ORi) containing (in mM): 90 NaCl, 1 KCl, 5 HEPES, and 1 EGTA (pH 7.4) for 10 min. Defolliculated oocytes 
were stored in a low-Na+ solution (in mM): 10 NaCl, 80 NMDG–Cl (N-methyl-d-glucamine), 1 KCl, 2 CaCl2, 
5 HEPES, 2.5 Na-pyruvate (Applichem, Darmstadt, Germany), 0.06 penicillin (Sigma-Aldrich), 0.02 streptomy-
cin (Sigma-Aldrich) at 17 °C (pH 7.4).
Plasmid DNA encoding the human Chrna9, human Chrna10 as well as the human 43 kDa receptor-associated 
protein of the synapse (RAPSN) were obtained from Eurofins Genomics (Ebersberg, Germany). Capped cRNA 
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:28660 | DOI: 10.1038/srep28660
was synthesized using an in vitro transcription kit (T7-RiboMAX™ Large Scale RNA Production System Kit, 
PROMEGA, Mannheim, Germany).
Oocytes of stages V and VI (Dumont 1972) were injected with cRNA encoding α 9 nAChR subunits (20 ng 
per oocyte) or α 9α 10 nAChR subunits (each 20 ng per oocyte) using a microinjector (Nanoject, Drummond 
Scientific, Broomall, USA). In order to increase expression levels and obtain stable nAChR expression, cRNA 
encoding RAPSN (5 ng per oocyte) was co-injected in both cases47,48. All cRNA was dissolved in nuclease-free 
water. The injection volume was 50.6 nl. In all TEVC experiments representative controls were performed with 
oocytes that were injected with 50.6 nl of nuclease-free water.
After an incubation time of 3–5 days, the transmembrane currents (IM) of water- or RNA-injected oocytes 
were recorded by the TEVC technique. Oocytes were placed in a perfusion chamber and perfused (gravity driven) 
with ORi containing (in mM): 90 NaCl, 1 KCl, 2 CaCl2, and 5 HEPES (pH 7.4). Intracellular microelectrodes were 
pulled from borosilicate glass capillaries and filled with 1 M KCl solution. The membrane voltage was clamped 
to − 60 mV using a TEVC amplifier (Warner Instruments, Hamden, USA), and transmembrane currents were 
low-pass filtered at 1000 Hertz (Frequency Devices 902, Haverhill, Massachusetts, USA) and recorded with a 
strip chart recorder (Kipp & Zonen, Delft, The Netherlands). In all experimental groups, measurements were 
performed on oocytes from at least two different Xenopus laevis individuals.
For experiments examining the effects of continuous exposure to PC on α 9- and α 10-mediated currents, 
oocytes were injected with a 1:1 ratio of cRNA for human α 9 and α 10 nAChR subunits and incubated at 17 °C 
for 3 days. To conduct TEVC experiments, the oocytes were placed in a 30 μ l chamber and continuously perfused 
by gravity with a solution containing 96 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl2, and 1 mM MgCl2. The pH of the 
solution was adjusted to 7.4 with NaOH. A stock solution of 100 mM PC was prepared in distilled water. A work-
ing solution of 1 mM PC was prepared in perfusion solution containing lower CaCl2 (0.8 mM) such that the final 
concentration of Ca2+ in all solutions was 1.8 mM. The oocyte membranes were clamped at a holding potential 
of − 70 mV and stimulated with 1 s pulses of 1 mM Cho once every 60 s until a steady-state baseline response was 
observed. The perfusion solution was then switched on one containing 1 mM PC and the oocytes stimulated with 
1 s pulses of 1 mM Cho plus 1 mM PC and the Cho-evoked responses monitored for changes in amplitude. The 
data for inhibition of the Cho-evoked responses were normalized to 3 averaged control pulses and analysed with 
an exponential decay equation. Data for recovery from inhibition were analysed with an exponential association 
equation. The data for inhibition by PC were best fit with a double exponential and the data for recovery from 
inhibition with a single exponential.
Statistical analyses. Data were analysed with the SPSS software (Munich, Germany) or GraphPad Prism 
6 software (Ja Lolla, CA, USA). Values derived from different cells were compared, where applicable, by the non-
parametric Kruskal-Wallis test, followed by the Mann-Whitney rank-sum test. The Wilcoxon signed-rank test 
was used for analyses of dependent values. The number (n) of individual experiments is indicated in the Results 
section and the Figures. In TEVC measurements oocytes from at least two different Xenopus laevis individuals 
were used.
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